What's Happening?
Researchers at The Ohio State University Comprehensive Cancer Center have identified a potential new target for treating glioblastoma, one of the deadliest forms of brain cancer. The study, published in Cancer Letters, highlights the role of the protein
SET in making glioblastoma cells more vulnerable to treatment. By suppressing SET, researchers found that tumor formation was prevented in preclinical models. The study also explored the role of PP2A, an enzyme that glioblastoma cells block through proteins like ANP32A, CIP2A, and SET. Blocking these proteins increased the cancer cells' sensitivity to radiation, suggesting a new pathway for drug targeting. The research is still in its early stages and has not yet been tested in human patients.
Why It's Important?
This discovery is significant as it offers a new avenue for enhancing the effectiveness of existing glioblastoma treatments, which currently have limited success due to the cancer's resistance to radiation and chemotherapy. By potentially restoring PP2A activity, the research could lead to improved survival rates for patients with this aggressive cancer. The study also opens up possibilities for developing drugs that target the identified pathway, which could revolutionize treatment protocols and offer hope to those affected by glioblastoma.
What's Next?
The research team is now focused on determining whether targeting SET and related proteins can be done safely in humans and whether this approach can improve responses to standard glioblastoma treatments. They are also exploring the use of an FDA-approved antipsychotic drug that can increase PP2A activity, although it is not yet ready for use in glioblastoma patients outside of clinical trials. Further studies are needed to confirm these findings and to develop potential new therapies based on this research.
